Venture Capital in Life Sciences; A case study with Novartis Venture Fund
Event details
| Date | 19.09.2018 |
| Hour | 10:30 › 12:30 |
| Speaker | Dr Beat Steffen |
| Location | |
| Category | Conferences - Seminars |
Catalyze4Life (https://catalyze4life.epfl.ch/) is happy to announce the following Life Sciences Innovation Workshop:
Title: “Venture Capital in Life Sciences; A case study with Novartis Venture Fund”
Speaker: Dr Beat Steffen- Novartis Venture Fund; Principal
Place: AI 1153 https://plan.epfl.ch/?room=AI1153
Date: Wednesday, 19.09.2018
Time: 10:30-12:30
Background: Catalyze4Life works to increase the applicability value of innovative projects, to help bridging the gap between research and industrial development. Thus, catalyzing innovative life sciences discoveries for society.
When the value of a project is determined as based on a careful diligence process, an appropriate path to technology transfer may be determined. The creation of a startup may be, then, privileged.
Through this workshop, Beat/Novartis Venture Fund, wishes to help, interested in applicable life sciences research, scientists understanding how life sciences investment experts calculate, or develop, the value of a project, through identifying or structuring specific project elements.
This workshop shall be interactive. Preparation material shall be distributed to participants before the event.
The Workshop shall be limited to 30 participants (1st come 1st served). Participants with applicable projects are encouraged.
You can participate at: https://epfl.doodle.com/poll/5t4b84sanrg25sds
Looking forward to your participation,
Bart Deplancke & Kostas Kaloulis
Beat's Biography:
Dr. Beat Steffen is a Principal in Basel, Switzerland. Prior to joining Novartis Venture Fund, he worked at Novartis Pharmaceuticals in commercial roles in the US and in Switzerland launching several products mainly in the cardiovascular area. Beat joined Novartis from Wellington Partners Venture Capital where he worked with biotech and medical device startup companies. Prior to that, he was at McKinsey & Company in Zurich working with clients in the pharmaceutical industry. Beat is a Swiss-trained physician having focused in cardiovascular surgery and intensive care. He graduated from the University of Zurich Medical School and qualified as a Medical Doctor in Basel. Beat holds an MBA with distinction from INSEAD. Beat serves on the boards of Aelin Therapeutics, and the University of Zurich Life Sciences Fund.
Novartis Venture Fund:
Novartis Venture Funds is a private equity and venture capital arm of Novartis AG specializing in investments in early startup companies, seed, growth capital, Series A, and later stage investment. The firm is stage agnostic and makes early, mid and late venture investments. It seeks to invest in
biotech/biopharma, medical devices and diagnostics, and life sciences companies with a focus on new novel therapeutics and platforms; medical devices and implants; diagnostics and biomarkers; and drug delivery and biopolymers. www.nvfund.com
Key words: Life Sciences Innovation, Startups, Technology Transfer, Valuation, Business Case, Investment Case, New therapeutics & platforms, Medical devices/implants, Diagnostics/biomarkers, Drug delivery/biopolymers
Practical information
- General public
- Registration required
Organizer
- Catalyze4Life; https://catalyze4life.epfl.ch/
Contact
- Bart Deplancke & Kostas Kaloulis